Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $187.94 USD
Change Today +1.68 / 0.90%
Volume 1.5M
PRGO On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
Frankfurt
As of 6:40 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$186.28
Previous Close
$186.26
Day High
$189.64
Day Low
$185.34
52 Week High
04/8/15 - $215.73
52 Week Low
05/8/14 - $125.37
Market Cap
27.5B
Average Volume 10 Days
4.2M
EPS TTM
$3.33
Shares Outstanding
146.3M
EX-Date
05/27/15
P/E TM
56.4x
Dividend
$0.50
Dividend Yield
0.23%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company’s Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company’s API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

10,220 Employees
Last Reported Date: 10/1/14
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $563.2K
Executive Vice President of Global Operations...
Total Annual Compensation: $470.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $470.3K
Executive Vice President and General Manager ...
Total Annual Compensation: $458.0K
Compensation as of Fiscal Year 2014.

perrigo co plc (PRGO) Key Developments

Perrigo Company plc Declares Quarterly Dividend, Payable on June 16, 2015

Perrigo Company plc announced that its board of directors declared a quarterly dividend of $0.125 per share, payable on June 16, 2015 to shareholders of record on May 29, 2015.

Perrigo Company plc Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 28, 2015; Provides Earnings Guidance for the Year 2015

Perrigo Company plc reported unaudited consolidated earnings results for the third quarter and nine months ended March 28, 2015. For the quarter, the company reported net sales of $1,049.1 million against $1,004.2 million a year ago. Operating income was $199.2 million against $103.3 million a year ago. Loss before income taxes was $102.7 million against income before income taxes of $62.7 million a year ago. Net loss was $94.9 million or $0.67 per basic and diluted share against net income of $48.1 million or $0.36 per basic and diluted share a year ago. For the nine-months, the company reported net sales of $3,072.3 million against $2,916.6 million a year ago. Operating income was $520.7 million against $369.5 million a year ago. Income before income taxes was $90.6 million against $106.9 million a year ago. Net income was $71.5 million or $0.52 per basic and diluted share against $73.4 million or $0.67 per basic and diluted share a year ago. Net cash from operating activities was $735.6 million against $400.8 million a year ago. Additions to property and equipment were $79.8 million against $120.0 million a year ago. On non-GAAP basis, operating income was $355.7 million against $335.2 million a year ago. Income before income taxes was $706.0 million against $529.1 million a year ago. Net income was $609.4 million against $432.1 million a year ago. On adjusted basis, net sales were $3,072.3 million against $2,916.6 million a year ago. Operating income was $876.4 million against $704.6 million a year ago. Income before income taxes was $796.6 million against $635.8 million a year ago. Net income was $680.9 million or $5.06 per diluted share against $505.3 million or $4.62 per diluted share a year ago. For the calendar year 2015, the company expects adjusted earnings per diluted share range of $7.50 to $8.00, an increase of 20% to 28% over calendar 2014 adjusted earnings per share. The company expects net sales for the year to be in the range of $5.4 billion to $5.7 billion with adjusted operating margin of approximately 27%.

Perrigo Company Public Limited Company to Report Q3, 2015 Results on Apr 21, 2015

Perrigo Company Public Limited Company announced that they will report Q3, 2015 results at 5:00 PM, US Eastern Standard Time on Apr 21, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $187.94 USD +1.68

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $86.31 USD +1.26
Hospira Inc $87.73 USD +0.44
Mead Johnson Nutrition Co $96.74 USD +0.49
Sigma-Aldrich Corp $138.97 USD +0.03
Sun Pharmaceutical Industries Ltd 947.75 INR +8.90
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 6.2x
Price/Book 2.7x
Price/Cash Flow 133.9x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.